About CytoPherx
CytoPherx is a company based in Ann Arbor (United States) founded in 1994. CytoPherx has raised $47.69 million across 3 funding rounds from investors including Early Stage Partners, ONSET Ventures and Capital Midwest Fund. CytoPherx has completed 1 acquisition, including Immunocept Medical Products. CytoPherx operates in a competitive market with competitors including Hemotune, Medcura, ExThera Medical, Lindis Blood Care and Arteriocyte, among others.
- Headquarter Ann Arbor, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$47.69 M (USD)
in 3 rounds
-
Latest Funding Round
$34 M (USD), Series B
Jan 06, 2012
-
Investors
Early Stage Partners
& 5 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of CytoPherx
CytoPherx has successfully raised a total of $47.69M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $34 million completed in January 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CytoPherx
CytoPherx has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Early Stage Partners, ONSET Ventures and Capital Midwest Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments in US tech companies are made.
|
Locked | Locked | Locked | |
|
Early stage VC firm investing in the US
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for CytoPherx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CytoPherx
CytoPherx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Immunocept Medical Products.
Investment portfolio details for CytoPherx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Blood filtration therapy for severe sepsis is developed.
|
Locked | Locked | 1999 | Locked |
Complete acquisition details for CytoPherx
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - CytoPherx
Detailed financials for CytoPherx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cytopherx Comparisons
Peer comparison for CytoPherx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CytoPherx
CytoPherx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hemotune, Medcura, ExThera Medical, Lindis Blood Care and Arteriocyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of a device for blood purification
|
|
| Locked | Locked | Locked |
Developer of the device for controlling bleeding
|
|
| Locked | Locked | Locked |
Medical devices for the rapid treatment of bloodstream infections and pathogen-reduction in blood banking
|
|
| Locked | Locked | Locked |
Innovative solutions for safer blood transfusions are developed.
|
|
| Locked | Locked | Locked |
Devices to facilitate blood component and bone marrow transplant
|
Detailed competitors of CytoPherx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cytopherx
Complete news archive for CytoPherx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CytoPherx
CytoPherx was founded in 1994 and raised its 1st funding round 15 years after it was founded.
CytoPherx is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Charles Fisher is the current CEO of CytoPherx.
CytoPherx is a funded company, having raised a total of $47.69M across 3 funding rounds to date.
Founded in 1994 as Nephrion and renamed CytoPherx in 2009, the company operates in the medical device sector from Ann Arbor, United States. Systems are designed to sequester and deactivate leucocytes in the circulatory system, utilizing hollow fiber dialysis filters. Targets include acute renal failure, end-stage renal disease, and inflammation from cardiopulmonary bypass surgery. Leadership is provided by CEO Charles Fisher.
CytoPherx's top competitors include Medcura, ExThera Medical and Lindis Blood Care.
CytoPherx has made 1 acquisition, including Immunocept Medical Products.
CytoPherx has 6 investors. Key investors include Early Stage Partners, ONSET Ventures, Capital Midwest Fund, Kaiser Permanente Ventures, and Emergent Medical Partners.